Literature DB >> 2346303

Changes in clonal composition during in vivo growth of mixed subpopulations derived from the murine K-1735 melanoma.

A Staroselsky1, S Pathak, I J Fidler.   

Abstract

We determined the conditions necessary for a metastatic clone of the K-1735 melanoma to become dominant over nonmetastatic clones. Different mixtures of metastatic and low or nonmetastatic cells which can be identified by detailed karyotype analysis were injected into the subcutis of syngeneic C3H/HeN and allogeneic nude mice. Early (small) and late (large) subcutaneous tumors were removed and enzymatically dissociated, and cell cultures were established. The clonal composition of the cultures was determined by cytogenetic analysis. In syngeneic mice, dominance by the metastatic clone occurred only when the initial inoculum consisted of at least 5% metastatic and 95% nonmetastatic cells. In nude mice, dominance by the metastatic clone occurred even with an inoculum of 1% metastatic and 99% nonmetastatic cells, suggesting that host immunity plays a major role in this tumor system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2346303

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Co-inoculation of human and murine carcinoma cells induces reciprocal suppression of metastasis by both cell lines.

Authors:  S M Nielsen-Preiss; J P Quigley; J E Testa
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

2.  Morphological heterogeneity and phenotypical instability versus metastatic stability in the murine tumor model ER 15-P.

Authors:  G Edel; A Roessner; B Deneke; B Wörmann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Interaction between three subpopulations of Ehrlich carcinoma in mixed solid tumours in nude mice: evidence of contact domination.

Authors:  K Aabo; L L Vindeløv; M Spang-Thomsen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.